<DOC>
	<DOCNO>NCT01500616</DOCNO>
	<brief_summary>The purpose study collect safety tolerability data telaprevir treatment combination Peg‑IFN‑alfa RBV patient HIV/genotype 1 chronic HCV coinfection severe fibrosis compensate cirrhosis eligible enrollment ongoing clinical study telaprevir .</brief_summary>
	<brief_title>Telaprevir Open-Label Study Co-Infected Patients</brief_title>
	<detailed_description>In study , patient receive open-label ( people involve know identity intervention ) telaprevir addition Peg IFN-alfa RBV treatment hepatitis C virus ( HCV ) protocol permissible treatment HIV . Chronic hepatitis C infection cause inflammation liver potentially cause long-term complication current liver disease ( fibrosis cirrhosis ) . Therefore important patient treat infection . Telaprevir experimental medication test treatment hepatitis C infection several previous study 2500 patient . Telaprevir member new class drug develop chronic hepatitis C : Direct Acting Antiviral ( DAA ) agent . Unlike pegylated interferon ( Peg-IFN ) ribavirin ( RBV ) , DAA agent act directly hepatitis C virus ( HCV ) replication cycle . The aim telaprevir treatment eradicate Hepatitis C virus patient 's body . This measure test amount certain part Hepatitis C virus , call Ribonucleic acid ( RNA [ HCV RNA ] ) blood . It possible patient respond therapy level HCV RNA blood decrease even increase . Based result might decide patient benefit treatment he/she need stop telaprevir medication hepatitis C infection . The doctor keep inform patient 's reaction treatment take necessary measurement prescribe study protocol routine medical practice . During study patient simultaneously treat therapy doctor would normally prescribe treatment chronic hepatitis C infection : `` ribavirin ( RBV ) '' `` pegylated interferon alfa ( PEG-INF-alfa ) '' . Telaprevir always administer combination RBV PEG-IFN-alfa . In function patient 's specific HIV status , doctor prescribed , , specific treatment patient continue take study . This treatment could : ( ) efavirenz , tenofovir disoproxil fumarate ( TDF ) , plus either emtricitabine lamivudine , ( b ) efavirenz , abacavir , plus either emtricitabine lamivudine , ( c ) ritonavir-boosted atazanavir , TDF , plus either emtricitabine lamivudine , ( ) ritonavir-boosted atazanavir , abacavir , plus either emtricitabine lamivudine , ( e ) raltegravir , TDF , plus either emtricitabine lamivudine , ( f ) raltegravir , abacavir , plus either emtricitabine lamivudine ( g ) etravirine , TDF , plus either emtricitabine lamivudin , ( h ) etravirine , abacavir , plus either emtricitabine lamivudine , ( ) rilpivirine , TDF , plus either emtricitabine lamivudine , ( j ) rilpivirine , abacavir , plus either emtricitabine lamivudine , ( k ) treatment . In interim analysis Phase 2a study , human immunodeficiency virus ( HIV ) -1/HCV genotype 1 coinfected patient currently receive HIV therapy telaprevir add Peg IFN-alfa-2a RBV regimen treatment HCV genotype 1 infection high HCV RNA response ( undetectable HCV RNA ) Weeks 4 12 receive Peg-IFN-alfa-2a RBV regimen . These response sustain Week 24 , 73.7 % patient telaprevir add Peg-IFN-alfa-2a RBV regimen 54.5 % patient receive Peg-IFN-alfa-2a RBV regimen also achieve undetectable HCV RNA Week 24 . Patients severe fibrosis cirrhosis lower likelihood sustain virologic response ( SVR ) also great risk liver failure , hepatocellular carcinoma ( HCC ) , death . Administering telaprevir difficult treat population may reduce risk long-term complication associate HCV patient HIV/HCV genotype 1 coinfection . All patient eligible enter study receive telaprevir ( 750 1,125 mg every 8 hour base Highly Active Antiretroviral Therapy ( HAART ) regimen ) first 12 week study combination Peg IFN alfa/RBV . Patients subsequently treat Peg-IFN-alfa/RBV additional 36 week . The total duration Peg-IFN-alfa/RBV 48 week . HCV RNA level measure Weeks 4 , 12 , 24 48 . All patient posttreatment follow-up visit , include measurement plasma HCV RNA level , perform 24 week last administer dose treatment . Note certain country , additional main objective study provide Early Access telaprevir population .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Have diagnosis HIV1 HIV2 infection , HIV1 HIV2 coinfection 6 month screen visit . Should stable permissible HAART regimen 8 week Day 1 without switch . OR Not HAART regimen expect start HIV treatment study , ie , CD4 count ≥500 cells/mm3 HIV1 and/or HIV2 viral load ≤50,000 copies/mL screen If stable permissible HAART regimen , CD4 count ≥200 cells/mm3 ≥15 % HIV1 and/or HIV2 viral load &lt; 50 copies/mL least 6 month start treatment recommend Have evidence HCV infection genotype 1 ( molecular assay ) Have quantifiable plasma HCV RNA Is eligible enrollment ongoing clinical study telaprevir Is infect coinfected HCV another genotype genotype 1 Has contraindication administration PegIFNalfa RBV , medical history laboratory value preclude treatment PegIFNalfa RBV accord respective local prescribe information Have contraindication currently prescribe HAART regimen screen . Note : Patients contraindication nonprescribed permissible HAART medication exclude . Positive human leukocyte antigen ( HLA ) B5701 genotyping result screening ( document result prior screen ) abacavir component HAART</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic Hepatitis C Infection</keyword>
	<keyword>Chronic Hepatitis C Co-Infected Patients</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Severe Fibrosis</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>VX-950HPC3005</keyword>
</DOC>